Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00765024

Enrollment

Registered

2008-10-02

Start date

2008-07-31

Completion date

2010-04-30

Last updated

2017-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Strongyloidiasis

Keywords

strongyloidiasis, ivermectin, albendazole

Brief summary

A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Interventions

DRUGIvermectin

single dose of 200 mcg/kg

DRUGivermectin

two single dose of 200mcg/kg in 2 weeks

DRUGAlbendazole

Albendazole 7 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Patients with positive strongyloides larva in the stool

Exclusion criteria

* Pregnancy * Lactating women * Known allergy to any study drug

Design outcomes

Primary

Measure	Time frame
cure rate	1 year

Secondary

Measure	Time frame
safety	1 year

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026